文献速递免疫规划

趋化因子CCL20质粒可提高Montanide ISA™ 206佐剂化口蹄疫疫苗在小鼠模型中的保护效力

Chemokine CCL20 plasmid improves protective efficacy of the Montanide ISA™ 206 adjuvanted foot-and-mouth disease vaccine in mice model.
PubMed 文献 · Vaccine · 2018-07-24

本研究在小鼠模型中评估趋化因子CCL20作为灭活口蹄疫疫苗佐剂的潜力,比较CCL20质粒与CCL20蛋白提前两天注射后接种Montanide ISA206佐剂化灭活口蹄疫疫苗的免疫应答。结果显示,CCL20质粒联合疫苗组较CCL20蛋白联合疫苗组产生更早且显著更高的中和抗体应答(p<0.05),CCL20蛋白无佐剂效应,其免疫应答与单独疫苗组相当;攻毒后CCL20质粒联合疫苗组获得完全保护(100%),而CCL20蛋白联合疫苗组或单独疫苗组保护率为66%。

要点

  • CCL20质粒联合口蹄疫疫苗组中和抗体应答显著高于CCL20蛋白联合疫苗组(p<0.05)。
  • CCL20蛋白联合疫苗组免疫应答与单独疫苗组相当,未显示佐剂效应。
  • 攻毒后CCL20质粒联合疫苗组保护率100%,CCL20蛋白联合疫苗组或单独疫苗组为66%。

核心结论

  • 提前注射CCL20质粒可提高灭活口蹄疫疫苗的保护效力,为调节灭活疫苗的免疫效力与极化提供了一种策略。

研究设计与样本

  • 小鼠分组经肌肉注射鼠源CCL20 DNA或CCL20蛋白,两天后接种Montanide ISA206佐剂化灭活口蹄疫疫苗,检测免疫后血清的体液与细胞免疫应答。

主要发现

  • CCL20质粒联合疫苗组较CCL20蛋白联合疫苗组显示更早且显著更高(p<0.05)的中和抗体应答。
  • CCL20蛋白联合疫苗组诱导的免疫应答与单独接种口蹄疫疫苗组相当。
  • 所有疫苗接种组均产生血清IgG1和IgG2抗体应答;CCL20质粒联合疫苗组IgG1和IgG2应答显著更高(p<0.05),且在所有时间点均保持较高水平,但并非始终具有统计学显著性。
  • 用灭活口蹄疫病毒抗原再刺激脾细胞后,CCL20质粒联合疫苗组培养上清中IFN-γ和IL-2水平显著更高(p<0.05),提示TH1型细胞免疫。
  • 免疫后第28天以同源口蹄疫病毒攻毒,CCL20质粒联合疫苗组显示完全保护(100%),而CCL20蛋白联合疫苗组或单独疫苗组保护率为66%。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This study aimed to investigate the chemokine CCL20, a macrophage inflammatory protein-3 alpha, for adjuvant potential in inactivated foot-and-mouth disease (FMD) vaccine. Groups of mice were injected intramuscularly with either murine CCL20 DNA or CCL20 protein two days ahead of the immunization with Montanide ISA206 adjuvanted inactivated FMD vaccine and humoral and cellular immune responses were measured in post-vaccinal sera. We demonstrated that the mice immunized with CCL20 plasmid plus FMD vaccine showed earlier and significantly (p < 0.05) higher neutralizing antibody responses compared to the mice vaccinated with CCL20 protein plus FMD vaccine. In fact, CCL20 as a protein did not show any adjuvant effect and the immune responses induced in this group were comparable to that of the mice vaccinated with FMD vaccine alone. All the vaccination groups showed serum IgG1 and IgG2 antibody responses; however, the mice vaccinated with CCL20 plasmid plus FMD vaccine showed significantly (p < 0.05) higher IgG1 and IgG2 responses and the responses remained high at all-time points post vaccination, although not always statistically significant. Upon restimulation of the vaccinated splenocytes with the inactivated FMD viral antigen, significantly (p < 0.05) higher IFN-γ and IL-2 levels in culture supernatants were found in animals vaccinated with the CCL20 plasmid plus FMD vaccine, which is indicative of the TH1 type of cellular immunity. On challenge with the homologous FMD virus on 28th day post immunization, CCL20 plasmid plus FMD vaccine showed complete protection (100%) while animals immunized with CCL20 protein plus FMD vaccine or FMD vaccine alone showed 66% protection. In summary, we show that prior injection of CCL20 plasmid improved protective efficacy of the inactivated FMD vaccine and thus offers a valuable strategy to modulate the efficacy and polarization of specific immunity against inactivated vaccines.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Jayeshbhai C, Hajam IA, Verma AK, et al. Chemokine CCL20 plasmid improves protective efficacy of the Montanide ISA™ 206 adjuvanted foot-and-mouth disease vaccine in mice model. Vaccine. 2018. PMID: 30054161. doi:10.1016/j.vaccine.2018.07.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。